Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 72

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 72
---
 for                                                                                                                                        
 a number of procedural, documentary, fee payment, and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; |

| • |     | it is possible that our pending patent applications or those that we may own or license in the future will not 
 lead to issued patents;                                                                                        |

| • |     | issued patents, if any arise in the future, that we either own or have exclusively licensed may be revoked,            
 modified, or held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties; |

| • |     | others may have access to the same intellectual property rights licensed to us in the future on a non-exclusive basis; |

| • |     | our competitors or other third parties might conduct research and development activities in countries where we do                                          
 not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; |

| • |     | we may not develop additional proprietary technologies that are patentable; |

| • |     | we cannot predict the scope of protection of any patent issuing based on our patent applications, including                                                                                                  
 whether the patent applications that we own, or, in the future, in-license will result in issued patents with claims that directed to our product candidate or uses thereof in the United States or in other 
 foreign countries;                                                                                                                                                                                           |

| • |     | there may be significant pressure on the U.S. government and international governmental bodies to limit the scope                                                              
 of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; |

| • |     | countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.      
 courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates; |

| • |     | the claims of any patent issuing based on our patent applications may not provide protection against competitors 
 or any competitive advantages, or may be challenged by third parties;                                            |

| • |     | if enforced, a court may not hold that our patents, if they issue in the future, are valid, enforceable, and 
 infringed;                                                                                                   |

| • |     | we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which 
 will be costly whether we win